Publicada en el periódico LA VANGUARDIA 15-12- 2015. Oncomatryx amplía capital para completar la fase preclínica de medicamentos contra el estroma tumoral La empresa vasca Oncomatryx ha finalizado una ronda de ampliación de capital de 4,5 millones de euros con el objetivo de completar los ensayos preclínicos de la «pionera» molécula denominada OMTX, que ha … Leer más
Published by La Vanguardia 2015-12-15. Oncomatryx expands capital to complete the preclinical phase of drugs against tumor stroma The Basque company Oncomatryx has completed a round of capital increase of 4.5 million euros with the aim of completing the preclinical trials of the “pioneer” molecule named OMTX, which has been developed against the tumor stroma, … Leer más
Contra el cáncer desde el stroma: nueva via para el cáncer de páncreas Por Laureano Simon, CEO de Oncomatryx Pancreatic cancer is the fourth most fatal cancer in men and women. Most patients with pancreatic cancer progress to either metastatic or locally advanced disease in the asymptomatic phase. Its prognosis has not improved over the … Leer más
War on cancer stroma: a novel pathway to treat pancreatic cancer By Laureano Simon, CEO at Oncomatryx Pancreatic cancer is the fourth most fatal cancer in men and women. Most patients with pancreatic cancer progress to either metastatic or locally advanced disease in the asymptomatic phase. Its prognosis has not improved over the past 20 years; … Leer más
Esta empresa está capitalizada por INNVIERTE, INICIATIVA DE INVERSIÓN DE CDTI,
E.P.E.
